Skip to content

Study · Non-randomized trial · n = 20 · 1997

2 results

[Cerebrolysin in treatment of painful diabetic neuropathy].

Biesenbach G, Grafinger P, Eichbauer-Sturm G, Zazgornik J

Wiener medizinische Wochenschrift (1946)1 Jan 1997Cited by 8 (Europe PMC)

PMID9173675 (opens in a new tab)PepBankPUB-09173675
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with painful diabetic neuropathy, total FIS score fell from 8.7 to 5.1 after 6 weeks with Cerebrolysin, and from 7.9 to 6.6 in the placebo group.

    In plain wordsIn patients with diabetic neuropathy, symptom scores fell after Cerebrolysin and also fell in the placebo group.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseTotal FIS score
    Study

    n = 20

    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    20 ml daily · infusion · 10 daysAs given in this study (human).

    Measurements

    FIS score
    8.7 score
    start
    FIS score
    5.1 score
    6 weeks
    Reported +/- term for total FIS score
    1.9 score
    Cerebrolysin, start of therapy; uncertainty type not stated
    Reported +/- term for total FIS score
    2.2 score
    Cerebrolysin, after 6 weeks; uncertainty type not stated
    p value for total FIS score decrease
    < 0.001 p value
    Cerebrolysin, start of therapy versus after 6 weeks
    Total FIS score
    7.9 score
    Placebo, beginning of therapy
    Reported +/- term for total FIS score
    1.2 score
    Placebo, beginning of therapy; uncertainty type not stated
    Total FIS score
    6.6 score
    Placebo, 6 weeks later

    2 more measurements in the study.

    Source sentences

    Summary
    Cerebrolysin was associated with a significant decrease in total FIS score from 8.7 +/- 1.9 at the start of therapy to 5.1 +/- 2.2 after 6 weeks (p < 0.001),
    Summary
    In contrast in the placebo group the total FIS score decreased only from 7.9 +/- 1.2 at the beginning to 6.6 +/- 1.1 (p < 0.05) 6 weeks later
    2 context sentences
    Summary · context
    In a placebo-controlled longitudinal study we investigated the effect of that drug for treatment of painful diabetic neuropathy in 20 type-II diabetic patients (9 women, 11 men, mean age 63 +/- 9 years, duration of diabetes 14 +/- 7 years).
    Summary · context
    Patients received daily a cerebrolysin-infusion (20 ml in 500 ml Ringer) over a period of 10 days.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with painful diabetic neuropathy, Cerebrolysin reduced VAS pain score from 4.2 to 2.8 after 6 weeks.

    In plain wordsIn patients with diabetic neuropathy, pain scores decreased after Cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseVAS pain score
    Study

    n = 20

    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    20 ml daily · infusion · 10 daysAs given in this study (human).

    Measurements

    VAS score
    4.2 score
    start
    VAS score
    2.8 score
    6 weeks
    Reported +/- term for VAS score
    0.8 score
    Cerebrolysin, start of therapy; uncertainty type not stated
    Reported +/- term for VAS score
    0.9 score
    Cerebrolysin, after 6 weeks; uncertainty type not stated
    p value for VAS score reduction
    < 0.001 p value
    Cerebrolysin, start of therapy versus after 6 weeks
    VAS score
    4.5 score
    Placebo, beginning of therapy
    Reported +/- term for VAS score
    0.6 score
    Placebo, beginning of therapy; uncertainty type not stated
    VAS score
    4 score
    Placebo, 6 weeks later

    1 more measurement in the study.

    Source sentences

    Summary
    and to a reduction of the VAS score from 4.2 +/- 0.8 to 2.8 +/- 0.9 (p < 0.001) during the same period of observation.
    Summary
    In contrast in the placebo group the total FIS score decreased only from 7.9 +/- 1.2 at the beginning to 6.6 +/- 1.1 (p < 0.05) 6 weeks later and the VAS score from 4.5 +/- 0.6 to 4.0 +/- 0.5 (NS).
    2 context sentences
    Summary · context
    In a placebo-controlled longitudinal study we investigated the effect of that drug for treatment of painful diabetic neuropathy in 20 type-II diabetic patients (9 women, 11 men, mean age 63 +/- 9 years, duration of diabetes 14 +/- 7 years).
    Summary · context
    Patients received daily a cerebrolysin-infusion (20 ml in 500 ml Ringer) over a period of 10 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.